Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EAU guidelines on prostate cancer.

G Aus, C C Abbou, M Bolla

    European Urology
    |July 28, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    Evaluation of ocular and systemic endpoints after radiation of posterior uveal melanoma - A systematic review and meta-analysis.

    Heliyon·2024
    Same author

    Detection and size measurements of kidney stones on virtual non-contrast reconstructions derived from dual-layer computed tomography in an ex vivo phantom setup.

    European radiology·2022
    Same author

    The current role of precision surgery in oligometastatic prostate cancer.

    ESMO open·2022
    Same author

    Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer.

    World journal of urology·2021
    Same author

    [Influence of the working model on the education of young urologists : Education through the ages].

    Der Urologe. Ausg. A·2021
    Same journal

    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

    European urology·2026
    Same journal

    Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

    European urology·2026
    Same journal

    In Memory of Paul Mitrofanoff (1934-2025).

    European urology·2026
    Same journal

    Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

    European urology·2026
    Same journal

    Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

    European urology·2026
    Same journal

    Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

    European urology·2026
    See all related articles

    The 2005 European Association of Urology (EAU) prostate cancer guidelines update emphasizes ultrasound-guided biopsies for diagnosis and recommends active treatment for localized disease. Follow-up relies on prostate-specific antigen (PSA) monitoring.

    Area of Science:

    • Urology
    • Oncology
    • Clinical Guidelines

    Background:

    • The European Association of Urology (EAU) first published prostate cancer guidelines in 2001.
    • Continuous updates are necessary due to significant advancements in prostate cancer management.
    • This paper summarizes the 2005 EAU guidelines update.

    Discussion:

    • Systemic prostate biopsies guided by ultrasound are the primary diagnostic method.
    • Periprostatic local anesthetic injection is recommended to reduce procedural discomfort.
    • Active treatment, including radical prostatectomy, is advised for localized prostate cancer with favorable life expectancy.

    Key Insights:

    • Radical prostatectomy is the sole treatment validated by randomized controlled trials.
    • Patient follow-up primarily involves prostate-specific antigen (PSA) monitoring and clinical history.

    Related Experiment Videos

  • Imaging is reserved for symptomatic patients.
  • Cytotoxic therapy is an option for specific cases of hormone-refractory prostate cancer.

    • Outlook:

    • The field of prostate cancer research is evolving rapidly.
    • The updated guidelines integrate the latest findings into clinical practice.
    • Evidence-based recommendations are enhanced with levels of evidence and grades of recommendation.